Nuclear imaging in Parkinson’s disease- The past, the present, and the future.
Published by Isotopia, 16th May 2022 Published by Isotopia, 16th
May 16, 2022
Overcoming Lutetium-177 Production and Supply Challenges
Published by Isotopia, 21th April 2022 Published by Isotopia, 21th
April 21, 2022
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Take home message: Take home message: The vision study is
August 3, 2021
Vision study – Research on Prostate Cancer
177Lu-PSMA-617 radioligand therapy in mCRPC – VISION phase 3 trial
April 16, 2020
April 6, 2020
February 16, 2020
Lutetium 177 production (Lu177 production)
Carrier Added (CA) and Non-Carrier Added (NCA) The production of
February 10, 2020
PERSONALIZED NUCLEAR MOLECULAR CANCER THERAPY
For decades, physicians and patients knew three classic treatments for
February 3, 2020
Prostate cancer
Innovative metastatic prostate cancer treatment with 177-Lu-PSMA. Prostate cancer is the most
February 3, 2020
